Literature DB >> 17410605

Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry.

Bettina Link1, Manuel Haschke, Markus Wenk, Stephan Krähenbühl.   

Abstract

Midazolam (MDZ), a short-acting benzodiazepine, is a widely accepted probe drug for CYP3A phenotyping. Published methods for its analysis have used either therapeutic doses of MDZ, or, if employing lower doses, were mostly unable to quantify the two hydroxy metabolites. In the present study, a sensitive and specific liquid chromatography/electrospray ionization tandem mass spectrometry method was developed and validated for the quantitative determination of MDZ and two of its metabolites (1'-hydroxymidazolam (1'-OHMDZ) and 4-hydroxymidazolam (4-OHMDZ)) in human plasma and oral fluid. After liquid-liquid extraction with hexane/dichloromethane (73:27, v/v), the analytes were separated on a Luna C18(2) (100 x 2.1 mm) analytical column using gradient elution. Detection was achieved using tandem mass spectrometry on an ion trap mass spectrometer. Midazolam-d6 was used as internal standard for quantification. The calibration curves were linear (R2 >0.998) between 0.05 and 20 ng/mL for MDZ and both metabolites in both matrices. Using 1 mL samples, the limit of detection was 0.025 ng/mL and the limit of quantification was 0.05 ng/mL for MDZ and the hydroxy metabolites in both matrices. Intra- and inter-day accuracies, determined at three different concentrations, were between 92.1 and 102.3% and the corresponding coefficients of variation were <7.3%. The average recoveries were 90.6%, 86.7% and 79.0% for MDZ, 1'-OHMDZ and 4-OHMDZ in plasma and 95.3%, 96.6% and 86.8% for MDZ, 1'-OHMDZ and 4-OHMDZ, respectively, in oral fluid. The method was successfully applied to a pharmacokinetic study, showing that MDZ and its hydroxy metabolites can be determined precisely in in vivo samples obtained following a single oral or intravenous dose of 2 mg MDZ. The method appears to be useful for CYP3A phenotyping in plasma using sub-therapeutic MDZ doses, but larger studies are needed to test this assumption. Copyright 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17410605     DOI: 10.1002/rcm.2987

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  8 in total

1.  Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest.

Authors:  Philip E Empey; Tricia M Miller; Ashley H Philbrick; John A Melick; Patrick M Kochanek; Samuel M Poloyac
Journal:  Crit Care Med       Date:  2012-04       Impact factor: 7.598

2.  Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

Authors:  Bettina Link; Manuel Haschke; Nathalie Grignaschi; Michael Bodmer; Yvonne Zysset Aschmann; Markus Wenk; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2008-04-11       Impact factor: 4.335

3.  Reduction of hyperbilirubinemia with hypericum extract (St. John's Wort) in a patient with Crigler-Najjar syndrome type II.

Authors:  Oliver Kummer; Felix Hammann; Manuel Haschke; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2016-03-07       Impact factor: 4.335

4.  Development and validation of a sensitive assay for analysis of midazolam, free and conjugated 1-hydroxymidazolam and 4-hydroxymidazolam in pediatric plasma: Application to Pediatric Pharmacokinetic Study.

Authors:  Ganesh S Moorthy; Harini Jogiraju; Christina Vedar; Athena F Zuppa
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-09-28       Impact factor: 3.205

Review 5.  Oral fluid testing for drugs of abuse.

Authors:  Wendy M Bosker; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-09-10       Impact factor: 8.327

6.  Midazolam Efficacy Against Acute Hydrogen Sulfide-Induced Mortality and Neurotoxicity.

Authors:  Poojya Anantharam; Dong-Suk Kim; Elizabeth M Whitley; Belinda Mahama; Paula Imerman; Piyush Padhi; Wilson K Rumbeiha
Journal:  J Med Toxicol       Date:  2018-01-09

Review 7.  Sedation level with midazolam: A pediatric surgery approach.

Authors:  Carmen Flores-Pérez; Luis Alfonso Moreno-Rocha; Juan Luis Chávez-Pacheco; Norma Angélica Noguez-Méndez; Janett Flores-Pérez; María Fernanda Alcántara-Morales; Luz Cortés-Vásquez; Lina Sarmiento-Argüello
Journal:  Saudi Pharm J       Date:  2022-05-23       Impact factor: 4.562

8.  Bioanalysis in drug discovery and development.

Authors:  Saurabh Pandey; Preeti Pandey; Gaurav Tiwari; Ruchi Tiwari
Journal:  Pharm Methods       Date:  2010-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.